US health care reform debate overlooking 'The Real Story'

27 October 2009

As US lawmakers debate health care reform, business innovator Lou Weisbach and Clinton White House health care advisor Richard Boxer say that they see a glaring, missing element of the forthcoming health care legislation: reducing health care costs - and saving lives - by preventing and curing disease.

The chilling reality, they note, is that the percentage of Americans who die of cancer today is unchanged from 1950. There is nothing in current health care reform legislation that provides for real change in the way health care is approached in the USA. Chronic diseases affect over 110 million Americans and account for nearly 75% of the more than $2.1 trillion spent on health care in the USA, they note.

Mr Weisbach and Dr Boxer want to change that: they are co-creators of The American Center for Cures (ACC) initiative, which proposes that a "Manhattan Project" or "Moon Shot"-like urgency be applied to cure or prevent disease. Their idea is revolutionary: the creation of The ACC - led by a cabinet-level Director of the Cures - housed within the National Institutes of Health (NIH). The ACC's mission is to cure a minimum of three diseases within the next seven years.

Diseases for focus - chosen by a "Cures Council" - may likely focus on Alzheimer's, autism, various types of cancer, Crohn's disease, depression, diabetes, epilepsy, multiple sclerosis, Parkinson', and genetic diseases of childhood (such as cystic fibrosis).

The ACC concept has support from numerous lawmakers and health care experts, as well as citizens who are signing a petition at www.americancenterforcures.org to have the initiative included in health care reform legislation.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical